Investor relations

Investor Relations Contacts

Jump to Contacts

Key Facts

Go to page

Emerging Markets are key to the ongoing pipeline- and sales-driven transformation of AstraZeneca. Over the past years, our global sales base has changed from having most of sales coming from what we now call ‘Other’ medicines to our current setup where our business is focused on three main therapy areas: Oncology, New Cardiovascular, Renal & Metabolism, and Respiratory. In these therapy areas, Emerging Markets now outperform the rest of the world.

As we look ahead to pursuing our science-led strategy in the years up to 2025, we have identified three priority areas. We want to ensure that we broaden access to healthcare, minimise our environmental footprint, and ensure ethics and transparency underpin everything we do.

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

It takes passion, energy and knowledge to enable us to put science at the heart of everything we do. Visit the 'What science can do' section of our website to read about our exciting work in stories from our people and partners.